Literature DB >> 17046269

Design and synthesis of Rho kinase inhibitors (II).

Masayuki Iwakubo1, Atsuya Takami, Yuji Okada, Takehisa Kawata, Yoshimichi Tagami, Hiroshi Ohashi, Motoko Sato, Terumi Sugiyama, Kayoko Fukushima, Hiroshi Iijima.   

Abstract

In a previous study, we identified several structurally unrelated scaffolds of the Rho kinase inhibitor using pharmacophore information obtained from the results of a high-throughput screening and structural information from a homology model of Rho kinase. 1H-Indazole is one of the candidate scaffolds on which a new series of potent Rho kinase inhibitors could be developed. In this study, the detailed structure-activity relationship of 1H-indazole analogues was studied. During this study, we found that the cell-free enzyme inhibitory potential of Rho kinase inhibitors having the 1H-indazole scaffold did not necessarily correlate with their inhibitory potential toward the chemotaxis of cultured cells. The choice of the linker substructure was shown to be an important factor for the 1H-indazole analogues to inhibit the chemotaxis of cells. Optimization of the 1H-indazole inhibitors with respect to the in vitro inhibition of monocyte chemotaxis induced by MCP-1 was carried out. The inhibitory potential was improved both in the cell-free enzyme assay and in the chemotaxis assay.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17046269     DOI: 10.1016/j.bmc.2006.09.052

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  6 in total

1.  Elaborate ligand-based modeling reveal new submicromolar Rho kinase inhibitors.

Authors:  Rand Shahin; Saja Alqtaishat; Mutasem O Taha
Journal:  J Comput Aided Mol Des       Date:  2011-12-14       Impact factor: 3.686

2.  Fragment-based and structure-guided discovery and optimization of Rho kinase inhibitors.

Authors:  Rongshi Li; Mathew P Martin; Yan Liu; Binglin Wang; Ronil A Patel; Jin-Yi Zhu; Nan Sun; Roberta Pireddu; Nicholas J Lawrence; Jiannong Li; Eric B Haura; Shen-Shu Sung; Wayne C Guida; Ernst Schonbrunn; Said M Sebti
Journal:  J Med Chem       Date:  2012-02-15       Impact factor: 7.446

3.  Discovery of substituted 4-(pyrazol-4-yl)-phenylbenzodioxane-2-carboxamides as potent and highly selective Rho kinase (ROCK-II) inhibitors.

Authors:  Yangbo Feng; Yan Yin; Amiee Weiser; Evelyn Griffin; Michael D Cameron; Li Lin; Claudia Ruiz; Stephan C Schürer; Toshihiro Inoue; P Vasanth Rao; Thomas Schröter; Philip Lograsso
Journal:  J Med Chem       Date:  2008-10-04       Impact factor: 7.446

4.  A small molecule bidentate-binding dual inhibitor probe of the LRRK2 and JNK kinases.

Authors:  Yangbo Feng; Jeremy W Chambers; Sarah Iqbal; Marcel Koenig; HaJeung Park; Lisa Cherry; Pamela Hernandez; Mariana Figuera-Losada; Philip V LoGrasso
Journal:  ACS Chem Biol       Date:  2013-06-10       Impact factor: 5.100

5.  Discovery of Novel N-Substituted Prolinamido Indazoles as Potent Rho Kinase Inhibitors and Vasorelaxation Agents.

Authors:  Yangyang Yao; Renze Li; Xiaoyu Liu; Feilong Yang; Ying Yang; Xiaoyu Li; Xiang Shi; Tianyi Yuan; Lianhua Fang; Guanhua Du; Xiaozhen Jiao; Ping Xie
Journal:  Molecules       Date:  2017-10-19       Impact factor: 4.411

6.  Structural Determinants Influencing the Potency and Selectivity of Indazole-Paroxetine Hybrid G Protein-Coupled Receptor Kinase 2 Inhibitors.

Authors:  Renee Bouley; Helen V Waldschmidt; M Claire Cato; Alessandro Cannavo; Jianliang Song; Joseph Y Cheung; Xin-Qiu Yao; Walter J Koch; Scott D Larsen; John J G Tesmer
Journal:  Mol Pharmacol       Date:  2017-10-25       Impact factor: 4.436

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.